Goiter is an enlargement of the thyroid gland, either diffuse or nodular, representing the common outcome of different trophic stimuli and multiple pathogenetic pathways converging on hypertrophy, hyperplasia, and remodeling of follicular architecture. From a clinical perspective, goiter does not correspond to a single functional diagnosis: it may be associated with euthyroidism, hypothyroidism, or hyperthyroidism, and may reflect physiological adaptation to iodine deficiency, dyshormonogenetic processes, thyroid autoimmunity, or nodular functional autonomy developing over time. Recognition of goiter therefore requires integration of its morphological features with functional assessment and investigation of the etiological context, because the same anatomical “form” may have very different prognostic and therapeutic implications.
From a public health perspective, goiter has historically been associated with iodine deficiency disorders and remains a sensitive indicator of the balance between iodine intake, the body’s physiological requirements, and the adaptive capacity of thyroid follicular cells. In iodine-sufficient settings, the epidemiology of goiter is now dominated by multinodular forms in adulthood, which are often progressive, and by conditions that increase the likelihood of nodularity. The clinically crucial issue is to distinguish a “stable,” minimally symptomatic goiter from a progressive goiter associated with a risk of compression, functional autonomy, or the need for cytological assessment of high-risk nodules.
The epidemiology of goiter varies markedly according to the iodine nutritional status of the population, iodine prophylaxis strategies, and access to sensitive diagnostic tools such as ultrasonography. In settings with inadequate iodine intake, goiter represents a long-term adaptation to insufficient availability of the substrate required for hormone synthesis: reduced iodination of thyroglobulin and decreased efficiency of thyroxine (T4) and triiodothyronine (T3) production promote increased thyrotropic stimulation, with progressive expansion of thyroid mass. In these areas, prevalence is highest in school-age children and adolescents, is greater among women, and may increase during periods of higher physiological demand, such as pregnancy and lactation, when thyroid homeostasis is subjected to greater requirements.
In countries with established iodine prophylaxis, the proportion of goiter attributable to severe iodine deficiency decreases, but individual vulnerability does not disappear. Variability in dietary intake, eating habits, reduced salt consumption as part of cardiovascular prevention strategies, and exposure to substances that interfere with iodine uptake or organification may leave a segment of the population at risk of “functional deficiency,” particularly vulnerable subgroups. At the same time, in iodine-sufficient settings, adult multinodular goiter becomes the dominant phenotype: it is often the result of years or decades of stimulation distributed unevenly among thyroid follicular cell clones, with selection of proliferative areas and formation of nodules with differing capacities for iodine uptake and thyroid-stimulating hormone response.
Female sex is a consistent risk factor, plausibly because of the interaction among sex hormones, autoimmunity, and thyroid growth dynamics throughout life. Age is equally important: the likelihood of nodularity increases over time and is strongly influenced by the sensitivity of ultrasonography, which identifies nodules even in asymptomatic individuals. In practical terms, multinodular goiter is often a condition of middle-aged and older adults, whereas diffuse forms may be more frequent in younger individuals when driven by adaptation to iodine deficiency or subclinical dyshormonogenesis.
A range of risk factors acts as a “biological background” facilitating thyroid growth. A family history of goiter and nodularity suggests a polygenic component, potentially including variants involved in thyroid follicular cell biology, regulation of thyroid-stimulating hormone signaling, or iodine organification mechanisms. A history of exposure to ionizing radiation during childhood or adolescence is primarily a determinant of nodularity and neoplastic risk, but it may also form part of the natural history of a nodular goiter requiring careful assessment. Environmental factors include chronic intake of goitrogenic substances and the presence of comorbidities or treatments that alter iodine availability or thyroid responsiveness.
From a clinical perspective, certain settings specifically increase the probability of goiter with functional autonomy. A long-standing multinodular goiter may progressively develop autonomous areas, with gradual suppression of thyroid-stimulating hormone and emergence of subclinical hyperthyroidism or overt hyperthyroidism, particularly after iodine exposure. This process makes excess iodine exposure epidemiologically relevant, whether resulting from iodinated contrast media or iodine-rich medications such as amiodarone, which may “unmask” pre-existing autonomy in a predisposed multinodular thyroid.
Finally, in patients with autoimmune thyroid disease, morphology may evolve in two opposite directions: autoimmunity may be associated with diffuse goiter due to hyperplasia and infiltration, or with progressive volume reduction due to parenchymal destruction and fibrosis. The epidemiological interpretation of goiter must therefore always be considered in light of the patient’s functional and immunological profile, because the same thyroid size may conceal biologically distinct conditions.
Goiter develops when thyroid growth exceeds the normal balance among proliferation, differentiation, and apoptosis of thyroid follicular cells, with follicular remodeling and variable colloid accumulation. The common final pathway is activation of trophic signals that increase deoxyribonucleic acid synthesis, production of thyroid-specific proteins, and expansion of glandular mass. Under physiological conditions, the main trophic signal is thyroid-stimulating hormone (TSH), which acts through the thyroid-stimulating hormone receptor and the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) cascade, modulating expression of the sodium-iodide symporter (NIS), thyroid peroxidase, and thyroglobulin, while also supporting cell survival. However, the pathogenesis of goiter cannot be reduced to “high TSH”: in many multinodular forms, thyroid function is euthyroid and TSH is normal, yet growth continues because of microheterogeneity in cellular responsiveness, local stimuli, and clonal selection over time.
Among the etiological causes, iodine deficiency represents the paradigm. Reduced iodide availability limits organification and decreases the efficiency of T4 synthesis, promoting increased thyrotropic stimulation even when serum values remain apparently “within range” because of compensation. The thyroid follicular cell increases iodide uptake and modifies the pattern of hormone synthesis by favoring, whenever possible, the production of T3 over T4, because fewer iodine atoms are required per molecule. This adaptability has a biological cost: chronic stimulation sustains hyperplasia and hypertrophy and, through repeated cycles of growth and involution, promotes structural heterogeneity with hypercolloid areas, fibrosis, intranodular hemorrhage, and calcification. Over the long term, the accumulation of these microevents transforms a diffuse goiter into a multinodular goiter with disorganized architecture.
Congenital or acquired dyshormonogenesis represents another etiology in which the primary defect affects biosynthetic steps: abnormalities of iodide uptake, organification defects, impaired iodotyrosine coupling, or disorders of thyroglobulin synthesis and secretion result in reduced effective hormone production and a compensatory increase in TSH. Even when the defect is partial, the hypothalamic-pituitary-thyroid axis tends to sustain thyroid growth in order to preserve euthyroidism, often producing goiter at a young age. In this setting, the pathophysiology of goiter reflects an “anatomical compensation” for a biochemical limitation.
In adult multinodular forms, pathogenesis is strongly influenced by the concept of clonal selection. Over the years, small groups of thyroid follicular cells may acquire proliferative or functional advantages associated with somatic variations that enhance responsiveness to TSH or partially activate intracellular signaling pathways. These clones may expand and form initially euthyroid nodules that can later become autonomous, reducing their dependence on TSH. The pathophysiological consequence is twofold: on the one hand, progressive enlargement with potential compression; on the other, progression toward subclinical or overt hyperthyroidism, particularly when iodine availability increases abruptly and provides autonomous nodules with sufficient substrate to enhance hormone synthesis.
An important pathogenetic aspect is the relationship between goiter and autoimmune inflammation. In autoimmune thyroid disease, lymphocytic infiltration and cytokine production may disrupt follicular homeostasis, alter permeability, and promote changes in gland volume. In Graves disease, stimulation of the TSH receptor by autoantibodies generates a powerful trophic and secretory signal, producing a diffuse hypervascular goiter associated with thyrotoxicosis. In other autoimmune settings, the course may differ, with phases of enlargement followed by volume reduction due to parenchymal destruction, illustrating how “goiter” is a morphological description that may belong to biologically opposite trajectories.
The pathophysiology of the clinical manifestations of goiter follows three principal pathways. The first is the mass effect: enlargement may compress the trachea and esophagus, cause displacement and narrowing of the airways, and become particularly relevant in retrosternal goiters, where the confined mediastinal space limits expansion and increases the likelihood of symptoms. The second is the functional component: associated hyperthyroidism or hypothyroidism alters metabolism and cardiovascular and neuromuscular function, and may dominate the clinical picture more than the mass itself. The third is the nodular component: the presence of nodules requires assessment of malignancy risk and ultrasonographic features, because part of the clinical burden of goiter arises from diagnostic evaluation of individual nodules rather than from overall gland volume.
In summary, goiter results from the interaction among substrate availability, particularly iodine, trophic signals such as TSH and local stimuli, genetic predisposition, and the temporal history of the gland. The same thyroid may progress through successive phases of adaptation, nodular transformation, and autonomy, making a dynamic interpretation that integrates etiology and pathophysiology with clinical presentation and imaging findings essential.
The clinical manifestations of goiter depend on the combination of gland volume, the anatomical distribution of enlargement, and thyroid functional status. Many patients are asymptomatic and discover the condition incidentally through self-observation of a neck swelling, during a medical examination, or on ultrasonography performed for other reasons. In such cases, the medical history should carefully investigate the chronology of growth, the rate of volume change, the presence of pain or inflammation, and the coexistence of systemic symptoms of thyroid dysfunction, because the “history” of the goiter often suggests the etiology even before testing is performed.
Symptoms caused by a mass effect are related to compression or displacement of adjacent structures. Patients may report cervical tightness, difficulty wearing tight collars, discomfort while swallowing, or a sensation of a “lump in the throat.” In larger goiters, particularly those with retrosternal extension, dyspnea due to tracheal compression, persistent cough, shortness of breath in the supine position, and, in selected cases, stridor or exertional respiratory difficulty may occur. Dysphonia requires particular attention because it may indicate recurrent laryngeal nerve involvement, compression, or other concomitant conditions, and in the presence of suspicious nodules it increases the need for thorough assessment.
The symptom profile may also include vascular or mediastinal manifestations in retrosternal goiters, such as a sensation of fullness, impaired venous return, or positional symptoms. In these circumstances, clinical assessment should consider the relationship between posture and symptoms, because dynamic compression may not be apparent under resting conditions. In addition to thyroid palpation, physical examination should include inspection of the neck during swallowing, assessment for tracheal deviation, and auscultation for vascular bruits in hypervascular goiters.
When goiter is associated with hyperthyroidism, systemic manifestations may dominate the clinical picture: tachycardia, heat intolerance, tremor, weight loss, irritability, fatigue, and reduced exercise tolerance. In autonomous multinodular goiter, the course may remain subclinical for a long time, with reduced TSH and normal peripheral hormone levels, but with a clinically relevant effect on the risk of atrial fibrillation and bone fragility in specific subgroups. Conversely, when hypothyroidism is present, patients may develop cold intolerance, somnolence, weight gain, dry skin, and bradycardia, with severity varying according to the degree of hormone deficiency.
On physical examination, goiter may appear as a diffuse, elastic enlargement, a multinodular gland with an irregular surface, or a dominant nodule within a background of multiple nodules. Consistency, mobility, tenderness, and the presence of lateral cervical lymphadenopathy help guide assessment, although palpation alone is insufficient to determine the nature of the nodules. Evaluation should also include extrathyroidal signs, such as ocular findings in cases compatible with Graves disease, or manifestations of other systemic disorders when infiltrative or inflammatory causes are suspected.
Finally, it is important to recognize “atypical” presentations in which goiter is associated with symptoms not immediately attributed to the thyroid. Chronic fatigue, blood pressure instability, palpitations, or mood disturbances may result from underlying thyroid dysfunction even when gland enlargement is modest. In such cases, an orderly reconstruction of the medical history, integrated with laboratory and imaging data, prevents fragmented interpretations and allows symptoms to be correctly attributed to the pathophysiological context.
Goiter should be suspected when there is visible or palpable enlargement of the anterior neck, asymmetry of the neck that moves with swallowing, or progressive compressive symptoms not explained by other causes. In practical terms, suspicion should be high when patients report positional dyspnea, difficulty swallowing, a sensation of tightness, or voice changes, particularly when symptoms progress slowly over time. A mass that appears to “descend” behind the sternum or becomes more evident during neck hyperextension suggests an intrathoracic component requiring targeted assessment.
Suspicion should also be actively considered in the absence of local signs when clinical features compatible with thyroid dysfunction emerge and palpation reveals an enlarged or irregular thyroid. Palpitations, tachycardia, tremor, and weight loss suggest toxic goiter or a stimulating autoimmune disorder, whereas somnolence, weight gain, and cold intolerance may accompany goiter formation in hypothyroid settings, including iodine deficiency or chronic thyroiditis. In older adults, hyperthyroidism may be oligosymptomatic and present mainly with arrhythmias or worsening of pre-existing cardiovascular disease, making autonomous multinodular goiter an important consideration even when classic symptoms are attenuated.
Certain historical factors substantially increase the likelihood of goiter and guide clinical attention. A history of residence or prolonged stay in areas at risk of iodine deficiency, a diet poor in iodized sources, recent pregnancy or plans for pregnancy, and a family history of goiter or thyroid nodules make clinically significant thyroid enlargement more likely. Exposure to iodine loads, such as iodinated contrast media, may precipitate thyrotoxicosis in individuals with multinodular goiter; therefore, the development of hypermetabolic symptoms after such exposure is a particularly useful clinical clue.
Suspicion must be especially high when goiter is associated with nodules showing potentially high-risk clinical features, such as rapid growth, hard consistency, fixation to deep tissues, or cervical lymphadenopathy. In these cases, the objective is not merely to confirm the presence of goiter, but to define the nodular architecture and cytological risk promptly. Even in the absence of “classic” warning signs, the combination of goiter and a dominant nodule requires a structured diagnostic pathway.
In summary, suspicion of goiter should be based not only on the morphology of the neck, but also on the temporal evolution of symptoms, the thyroid functional state suggested by the clinical picture, and the biological and iatrogenic contexts that increase the likelihood of thyroid growth and functional autonomy.
The diagnostic assessment of goiter integrates three domains: confirmation and morphological characterization, determination of thyroid function, and evaluation of nodules and local complications. The first clinical step is a thorough medical history and a physical examination focused on size, consistency, mobility, tenderness, and signs of compression. However, modern characterization of goiter is based on thyroid ultrasonography, which allows measurement of gland volume, distinction between diffuse and multinodular goiter, identification of nonpalpable nodules, and assessment of echostructural features relevant to risk stratification.
At the same time, functional assessment begins with measurement of TSH and, depending on the result, free thyroxine (FT4) and, when indicated, free triiodothyronine (FT3). A reduced TSH suggests functional autonomy or autoimmune stimulation and directs further investigation, whereas a normal TSH does not exclude nodularity and does not replace ultrasonographic evaluation of clinically relevant nodules. In the presence of symptoms or signs compatible with autoimmunity, testing for thyroid autoantibodies and, in cases of thyrotoxicosis, TSH receptor antibodies may help define the etiology and distinguish autonomous multinodular goiter from Graves disease.
The choice of second-line investigations depends on hormone levels and ultrasonographic findings. When TSH is reduced, thyroid scintigraphy using appropriate radioisotopes can distinguish hyperfunctioning areas compatible with an autonomous nodule or toxic multinodularity from diffuse uptake patterns, and may help identify hypofunctioning nodules requiring greater cytological attention. When TSH is normal or elevated, scintigraphy is generally not the first examination used for nodular risk stratification, whereas ultrasonography remains central in determining the indication for fine-needle aspiration.
Evaluation of thyroid nodules within a goiter requires an approach based on ultrasonographic features and size, with fine-needle aspiration indicated for nodules combining clinically significant dimensions with a suspicious ultrasonographic pattern. In multinodular goiter, the priority is to identify the nodules at highest risk rather than biopsy every nodule, because management must remain sustainable and clinically rational. Cytological findings guide subsequent care, ranging from surveillance to surgery, within a pathway in which oncological risk is assessed together with compressive and functional risks.
When goiter is large or retrosternal, assessment should include definition of intrathoracic extension and its effect on the airways. Ultrasonography may be insufficient to evaluate the entire mediastinal component; in such cases, computed tomography or other imaging techniques may be useful to quantify tracheal compression and plan a possible surgical approach. In patients with respiratory symptoms, pulmonary function testing and assessment of airflow obstruction may help objectively determine the severity of compression and support the indication for intervention even in the absence of oncological suspicion.
The differential diagnosis of goiter includes inflammatory, neoplastic, and infiltrative thyroid disorders that may present with gland enlargement. Pain, fever, marked tenderness on palpation, or rapid onset suggest thyroiditis or intranodular hemorrhage, whereas progressive enlargement with compressive symptoms may be compatible with either benign goiter or less common conditions. For this reason, combined interpretation of clinical findings, ultrasonography, and cytology is essential. The objective of diagnosis is not simply to “confirm goiter,” but to define the morphofunctional phenotype and overall clinical risk that guide treatment and follow-up.
Classification of goiter is useful because it summarizes anatomical and functional information into categories that guide management. The first distinction is morphological: diffuse goiter when enlargement involves the gland relatively uniformly, and nodular goiter when the architecture is characterized by one or more nodules. Nodular goiter may be solitary, with a dominant nodule, or multinodular, with multiple nodules and heterogeneous parenchyma. This classification often also reflects a temporal dimension, because a long-standing diffuse goiter may progress toward multinodularity through repeated cycles of growth and remodeling.
The second distinction is functional. A nontoxic goiter is associated with euthyroidism or hypothyroidism, whereas a toxic goiter is associated with hyperthyroidism, as occurs in toxic multinodular goiter or an autonomous nodule. There is also a clinically relevant intermediate state represented by subclinical hyperthyroidism, in which TSH is reduced but peripheral hormone levels remain within the reference range. In this setting, severity is defined not only by biochemical findings, but also by age, cardiovascular comorbidities, and skeletal risk, because the clinical impact may be relevant even when abnormalities appear “minimal.”
An additional classification describes location and extent. Goiter may be entirely cervical or may have a retrosternal or mediastinal component, which alters compressive risk and treatment planning. Retrosternal extension is important because the gland may enlarge within a rigid space, increasing the likelihood of tracheal compression and respiratory symptoms, and because dedicated imaging may be required to define its extent and relationship with vascular structures.
From a clinical perspective, severity may be assessed along three axes. The first is compressive severity, ranging from absence of symptoms to significant dyspnea and dysphagia with airway compromise. The second is functional severity, ranging from stable euthyroidism to hyperthyroidism with cardiovascular complications or clinically significant hypothyroidism. The third is “nodular” severity, which depends on malignancy risk and the need for diagnostic and therapeutic procedures, including biopsies, ablation, or surgery.
Finally, it is useful to distinguish iodine deficiency-related, autoimmune, and dyshormonogenetic forms, because each has a characteristic natural history and a different likelihood of progressing toward autonomy or volume reduction. This etiological classification is not merely theoretical: it guides preventive strategies, the need to assess iodine status, management during pregnancy, and attention to iodine exposure or medications that may abruptly alter thyroid balance.
Treatment of goiter depends on its etiology, functional status, compressive impact, and nodular profile. The objective is not always to reduce gland volume at all costs, but to balance safety, symptom control, and prevention of complications while avoiding unnecessary intervention in stable, low-risk goiters. In nontoxic, minimally symptomatic goiters, an observation strategy with clinical, laboratory, and ultrasonographic monitoring is often appropriate, particularly when gland volume is moderate and there are no signs of compression or suspicious nodules.
Correction of identifiable etiological determinants is central. In iodine-deficient settings, iodine prophylaxis through iodized salt and public health strategies reduces the incidence and progression of goiter in the population and represents the most effective measure at the collective level. In individual patients, assessment of iodine intake and correction of documented deficiency may be relevant, particularly during pregnancy, when requirements increase and maintenance of adequate iodine intake reduces the risk of thyroid abnormalities and fetal consequences. Individual management must nevertheless avoid excess intake, because a sudden increase in iodine availability in a multinodular thyroid may promote autonomy and thyrotoxicosis.
The use of levothyroxine for “suppressive” treatment of euthyroid goiter is a complex issue. Suppression of TSH may partially reduce growth in some patients, but exposes them to the risk of iatrogenic subclinical hyperthyroidism with adverse effects on the heart and skeleton, particularly in older adults. For this reason, the use of levothyroxine to reduce the volume of benign goiter requires strict patient selection, assessment of individual risk, and realistic goals, and does not represent a universal solution. In clinical practice, alternative strategies are generally preferred when compression is the dominant problem or when the risk associated with TSH suppression is unacceptable.
In goiters with functional autonomy and thyrotoxicosis, the priority is to control hyperthyroidism and prevent cardiovascular complications. In these cases, antithyroid agents may be used to control thyroid function, particularly initially or before surgery, but they do not always provide a definitive solution in autonomous multinodular goiter, where the gland may continue to contain areas functioning independently of pituitary control. Definitive options include radioiodine and surgery, selected according to goiter size, compression, age, comorbidities, patient preferences, and the need for rapid relief of the mass effect. In a large or retrosternal goiter with significant compression, surgery is generally the most definitive approach because it immediately removes the compressive component.
Surgery is also indicated when malignancy is suspected, when fine-needle aspiration or the ultrasonographic pattern indicates a non-negligible risk, or when progressive enlargement is associated with compressive symptoms. The extent of surgery depends on the clinical picture, nodular distribution, and risk profile, and requires planning in experienced centers to minimize complications such as hypoparathyroidism and recurrent laryngeal nerve injury. In selected patients with symptomatic, well-characterized benign nodules, minimally invasive procedures such as thermal ablation or ethanol ablation for cystic components may be considered, with the aim of reducing nodule volume and improving symptoms while avoiding major surgery. In this setting, the indication must be clearly defined and the diagnostic workup must have excluded malignancy.
In every scenario, the therapeutic strategy should include management of conditions that increase the risk of functional decompensation, such as iodine exposure and interfering medications, and should include specific plans for situations such as pregnancy or cardiovascular disease, in which thyroid balance has systemic consequences. Treatment of goiter is therefore a personalized pathway in which the choice among surveillance, medical therapy, radioiodine, interventional procedures, and surgery is based on integration of pathophysiology, clinical findings, and risk.
Follow-up of goiter aims to detect early increases in gland volume, development of compressive symptoms, functional progression toward autonomy or hypothyroidism, and nodular changes requiring reassessment. Monitoring should be proportionate to risk: a stable, diffuse, euthyroid goiter may require less frequent follow-up than a multinodular goiter with a dominant nodule or a condition with reduced TSH suggesting evolving autonomy.
Periodic assessment includes targeted clinical evaluation of dyspnea, dysphagia, voice changes, and symptoms of thyroid dysfunction. Reconstruction of the temporal history is essential: rapid worsening of compressive symptoms or evident enlargement requires earlier investigation and repeat imaging. In patients with retrosternal goiter, follow-up should account for the fact that increasing volume may be clinically underestimated on inspection and palpation, making imaging particularly important when symptoms change.
From a laboratory perspective, monitoring of TSH and, when appropriate, FT4 and FT3 allows early identification of subclinical or overt hyperthyroidism, or a trend toward hypothyroidism in autoimmune or dyshormonogenetic conditions. In multinodular goiters, a progressive decline in TSH suggests possible acquisition of autonomy and may require further evaluation with scintigraphy and reassessment of treatment strategy, particularly in patients at cardiovascular risk.
Ultrasonography remains the main tool for structural follow-up. It is useful for measuring gland volume, monitoring nodule growth, and detecting new ultrasonographic features that alter risk. In nodular follow-up, the decision to repeat fine-needle aspiration does not depend solely on size increase, but also on the emergence of suspicious ultrasonographic features or changes in the clinical context. Monitoring based exclusively on size may generate unnecessary procedures, whereas an integrated approach maintains focus on nodules that truly change the patient’s risk profile.
After definitive treatment, such as surgery or radioiodine, follow-up also focuses on residual function and the need for replacement therapy. In patients undergoing total thyroidectomy or extensive resection, management of levothyroxine requires dose adjustment with serial TSH measurements, whereas hypothyroidism may develop over time after radioiodine, necessitating prolonged monitoring. In patients treated with minimally invasive procedures for benign nodules, ultrasonographic follow-up documents volume reduction and long-term stability while maintaining surveillance of any concomitant nodules.
Patient education is an often underestimated component. Understanding the meaning of benign goiter, recognizing signs of progressive compression, and knowing when to report clinical changes improve follow-up safety and reduce inappropriate consultations or diagnostic delays. Effective monitoring is therefore a continuous process combining objective measurements with clinical observation and adapting to the natural evolution of the thyroid in each individual.
The prognosis of goiter is generally favorable when the etiology is correctly identified and follow-up is proportionate to risk, but it varies substantially according to gland volume, location, function, and nodular profile. Many nontoxic goiters remain stable for years with minimal impact on quality of life. However, some patients experience slow but continuous enlargement, which may eventually cause compressive symptoms or require definitive intervention. The natural course is particularly relevant in multinodular goiter, where heterogeneous architecture facilitates intranodular events such as hemorrhage or cystic degeneration, which may cause acute changes in volume and sudden symptoms.
The most clinically relevant local complication is tracheoesophageal compression, particularly in large and retrosternal goiters. Compression may progress gradually and present with worsening dyspnea, exercise limitation, and positional symptoms. In selected cases, airway narrowing may become clinically critical during respiratory infections or mucosal edema, making definitive treatment urgent. Compression of the recurrent laryngeal nerve, although less common as a primary event in benign goiter, is an important clinical complication because of its effect on the voice and because it always requires careful differential diagnosis, including nonbenign disorders.
A second area of complications concerns functional progression. Multinodular goiter may develop autonomous areas, leading to subclinical or overt hyperthyroidism. Even when symptoms are subtle, cardiovascular effects may be significant, with an increased risk of atrial fibrillation and worsening of pre-existing heart disease. In frail or older individuals, hyperthyroidism may present with weight loss, sarcopenia, and functional decline rather than classic signs, making the “functional” complication a prognostic determinant independent of goiter size.
The third area concerns the nodular component and oncological risk. Most nodules within a goiter are benign, but the presence of nodules requires risk stratification to identify the clinically relevant minority. Prognosis in this context depends on the quality of ultrasonographic and cytological assessment and on the ability to avoid both diagnostic delay and overtreatment. In other words, goiter generates a prognostic burden related to the decision-making process, not only to the condition itself.
Finally, treatment-related complications must be considered. Thyroid surgery, although definitive for compression and nodular risk, carries risks such as hypoparathyroidism and dysphonia, which should be minimized through surgical expertise and appropriate perioperative management. Radioiodine may lead to hypothyroidism over time and requires functional follow-up. Medical treatments that suppress TSH may cause iatrogenic subclinical hyperthyroidism, with cardiac and skeletal complications, which is why prognosis also depends on the appropriateness of the chosen strategy.
Overall, goiter is a condition that can usually be managed successfully, but it requires a structured approach because its main complications, compression and thyroid dysfunction, arise from an evolving pathophysiological process and can be prevented or treated effectively when recognized promptly.